Welcome, you are not signed in yet.
Log in? New User, Register?
Registration is FREE and offers great benefits
Today is: Tue, Sep 7, 2010 | 20:05 EDT
Add our site to your favorites
Your default homepage
Home
>>
Tech Directory
>>
Cytochroma Inc.
Business Description
Cytochroma Inc. is an integrated specialty pharmaceutical company engaged in the development and commercialization of proprietary products to treat and prevent the clinical consequences of diseases and disorders related to vitamin D deficiency.
Cytochroma has an advanced portfolio of new products targeting vitamin D deficiency and secondary hyperparathyroidism in patients with moderate to severe chronic kidney disease and end-stage renal disease. In addition, the company is developing novel vitamin D therapies to treat hyperproliferative disorders such as cancer and psoriasis.
Tech Directory
Cytochroma Inc.
| Last Update 2007/1/26 19:54 |
Category
Life Sciences
Biotechnology
Tel Number (905) 479-5306
Fax Number (905) 479-1287
Biotechnology
| Headoffice | |
| 330 Cochrane Drive, Markham, Ontario L3R 8E4 |
Cytochroma Inc. is an integrated specialty pharmaceutical company engaged in the development and commercialization of proprietary products to treat and prevent the clinical consequences of diseases and disorders related to vitamin D deficiency.
Cytochroma has an advanced portfolio of new products targeting vitamin D deficiency and secondary hyperparathyroidism in patients with moderate to severe chronic kidney disease and end-stage renal disease. In addition, the company is developing novel vitamin D therapies to treat hyperproliferative disorders such as cancer and psoriasis.
Executives and Directors
Charles W. Bishop, PhD, President & CEO, formerly co-founder and President of Proventiv Therapeutics (acquired by Cytochroma Inc. in June 2006)
Keith H. Crawford, B.S.,MBA, VP of Strategic Planning & Medical Marketing, formerly VP of Strategic Product Planning for Proventiv Therapeutics
Jukka Karjalainen, M., Ph.D., VP of Drug Development, formerly Director, Medical & Regulatory Affairs at Biovail Pharmaceuticals
Eric J. Messner, MBA, VP of Commercial Operations, formerly co-founder and VP of Commercial Operations of Proventiv Therapeutics
Martin Petkovich, Ph.D., co-founder, Chief Scientific Officer, Professor of Biochemistry and Pathology, Queen's University at Kingston
Jay White, Ph.D., VP of Product Development
Board of Directors
Martin Petkovich
Alan Lewis, Ph.D. (Chair), President & CEO, Novocell, Inc.
Rob Hall, MBA, Director, Venture Capital, Business Development Bank of Canada (BDC)
Søren Schifter, MD, GDBA, D.Msc., Partner, Novo Ventures, Novo A/S
Elizabeth Douville, Ph.D., VP, GeneChem Management Inc.
Joe Regan, MBA, VP of Investments, GrowthWorks Captial
Luc Marengère, Ph.D., General Partner, VenGrowth Capital Management Inc.
Financials
Founded in 1997 by PARTEQ Innovations, the technology development corporation of Queen's University at Kingston, Cytochroma secured an initial seed financing from University Medical Discoveries Inc. (UMDI)
Cytochroma closed its first round of financing in February 1999 with Canadian Medical Discoveries Fund (CMDF), GeneChem Technologies Venture Fund LP, and Working Ventures Canadian Fund Inc. (now GrowthWorks Canadian Fund Ltd.)
Cytochroma has raised $60 million in equity and bridge funding from investors including VenGrowth Advanced Life Sciences Fund, Novo A/S, GeneChem, CMDF, BDC Venture Capital, GrowthWorks, T2C2/Bio 2000 LP, CDP Capital - Technology Ventures, UMDI, and VentureLink LP.
Charles W. Bishop, PhD, President & CEO, formerly co-founder and President of Proventiv Therapeutics (acquired by Cytochroma Inc. in June 2006)
Keith H. Crawford, B.S.,MBA, VP of Strategic Planning & Medical Marketing, formerly VP of Strategic Product Planning for Proventiv Therapeutics
Jukka Karjalainen, M., Ph.D., VP of Drug Development, formerly Director, Medical & Regulatory Affairs at Biovail Pharmaceuticals
Eric J. Messner, MBA, VP of Commercial Operations, formerly co-founder and VP of Commercial Operations of Proventiv Therapeutics
Martin Petkovich, Ph.D., co-founder, Chief Scientific Officer, Professor of Biochemistry and Pathology, Queen's University at Kingston
Jay White, Ph.D., VP of Product Development
Board of Directors
Martin Petkovich
Alan Lewis, Ph.D. (Chair), President & CEO, Novocell, Inc.
Rob Hall, MBA, Director, Venture Capital, Business Development Bank of Canada (BDC)
Søren Schifter, MD, GDBA, D.Msc., Partner, Novo Ventures, Novo A/S
Elizabeth Douville, Ph.D., VP, GeneChem Management Inc.
Joe Regan, MBA, VP of Investments, GrowthWorks Captial
Luc Marengère, Ph.D., General Partner, VenGrowth Capital Management Inc.
Financials
Founded in 1997 by PARTEQ Innovations, the technology development corporation of Queen's University at Kingston, Cytochroma secured an initial seed financing from University Medical Discoveries Inc. (UMDI)
Cytochroma closed its first round of financing in February 1999 with Canadian Medical Discoveries Fund (CMDF), GeneChem Technologies Venture Fund LP, and Working Ventures Canadian Fund Inc. (now GrowthWorks Canadian Fund Ltd.)
Cytochroma has raised $60 million in equity and bridge funding from investors including VenGrowth Advanced Life Sciences Fund, Novo A/S, GeneChem, CMDF, BDC Venture Capital, GrowthWorks, T2C2/Bio 2000 LP, CDP Capital - Technology Ventures, UMDI, and VentureLink LP.
Hits: 9
Rating: 0.00 (0 votes)
Print
Tell a Friend
The comments are owned by the poster. We aren't responsible for their content.
| Poster | Thread |
|---|